• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Califf Calls Again for Use of RWE, Acceleration of Confirmatory Studies

Califf Calls Again for Use of RWE, Acceleration of Confirmatory Studies

July 18, 2022

Five months into his second go-round as FDA commissioner, Robert Califf once more stressed the importance of developing and employing a real-world evidence (RWE) system to support clinical research, especially for confirmatory trials of accelerated approvals.

Speaking at a virtual event hosted by the Alliance for a Stronger FDA, Califf contended that an RWE-gathering system could be used to ensure confirmatory studies for therapies granted accelerated approval are conducted in a much timelier manner. During his Senate confirmation hearings, the agency chief advocated for such a system that would tap into valuable electronic health record (EHR) data.

“I think we do a really good job of developing medical products up through the early phases, and that system works well,” Califf said. But when it comes to determining the right doses of drugs and how to combine and compare medical products, “I’d say we’re doing a lousy job of generating that evidence.”

“And yet,” he continued, “everyone in the United States has an EHR packed full of data that could be used to do studies very inexpensively.” But data privacy concerns over use of such data have exceeded those of public health interests, he acknowledged.

Califf also addressed issues with the FDA’s accelerated approval pathway, which has come under heavy scrutiny following the controversial clearance of Biogen’s Alzheimer’s drug Aduhelm (aducanumab) in June 2021. More and more of the agency’s approvals are accelerated, he pointed out, and with only early data to evaluate, it’s reasonably likely that a drug’s benefits will appear to outweigh the risks because it hasn’t yet been proven by postmarket confirmatory studies. And the agency’s approach to conducting confirmatory studies is “simply inadequate.”

“I think it was a signal to the very broad community when the initial statement was that it would take nine years to do the follow-up study on Aduhelm,” he said. “People said, ‘wait a minute, that doesn’t sound like a timeframe that’s reasonable.’”

 

To view more CenterWatch Weekly stories, click here.

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing